Treatment and outcome of intrahepatic cholangiocellular carcinoma

Treating intrahepatic cholangiocarcinoma (ihCCC) tumor resection leads to the best patient survival. The aim of this study was to investigate prognostic factors in resected patients. This was a clinical observational series of 31 resected patients with ihCCC. Univariate analysis of clinical and path...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2005-02, Vol.189 (2), p.173-177
Main Authors: Puhalla, Harald, Schuell, Birgit, Pokorny, Herwig, Kornek, Gabriela Verena, Scheithauer, Werner, Gruenberger, Thomas
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Chemotherapy
Cholangiocarcinoma
Cholangiocarcinoma - pathology
Cholangiocarcinoma - surgery
Disease-Free Survival
Dissection
Female
Gastroenterology. Liver. Pancreas. Abdomen
General aspects
Humans
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical imaging
Medical sciences
Middle Aged
Mortality
Neoplasm Recurrence, Local
NMR
Nuclear magnetic resonance
Postoperative period
Prognosis
Resection
Retrospective Studies
Survival
Survival analysis
Tomography
Treatment Outcome
Tumor-free survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treating intrahepatic cholangiocarcinoma (ihCCC) tumor resection leads to the best patient survival. The aim of this study was to investigate prognostic factors in resected patients. This was a clinical observational series of 31 resected patients with ihCCC. Univariate analysis of clinical and pathologic factors in relation to patient survival and tumor recurrence were performed. Possible benefit of chemotherapy, although not given randomly, was investigated separately. The median follow-up time was 37.3 months. Of 31 resected patients a tumor-free resection (R0) was achieved in 26; 2 patients died postoperatively. Chemotherapy was administered to 19 patients. Overall survival was significantly better in patients with R0 resection, negative lymph nodes, a solitary tumor, and a width of resection margin greater than 3 mm. Recurrence-free survival was prolonged in patients with negative lymph nodes, early International Union Against Cancer (UICC) stages and solitary tumors. In UICC stages III and IV, patients receiving chemotherapy experienced a better overall survival. Impact of various parameters on recurrence-free and overall survival was identified; a possible beneficial effect of adjuvant chemotherapy in advanced tumor stages was observed. A prospective, randomized trial is necessary to fully evaluate the role of adjuvant therapy.
ISSN:0002-9610
1879-1883
DOI:10.1016/j.amjsurg.2004.11.009